181 related articles for article (PubMed ID: 18953434)
1. Mutation and methylation analysis of the chromodomain-helicase-DNA binding 5 gene in ovarian cancer.
Gorringe KL; Choong DY; Williams LH; Ramakrishna M; Sridhar A; Qiu W; Bearfoot JL; Campbell IG
Neoplasia; 2008 Nov; 10(11):1253-8. PubMed ID: 18953434
[TBL] [Abstract][Full Text] [Related]
2. Chromodomain helicase DNA binding protein 5 plays a tumor suppressor role in human breast cancer.
Wu X; Zhu Z; Li W; Fu X; Su D; Fu L; Zhang Z; Luo A; Sun X; Fu L; Dong JT
Breast Cancer Res; 2012 May; 14(3):R73. PubMed ID: 22569290
[TBL] [Abstract][Full Text] [Related]
3. CHD5 is down-regulated through promoter hypermethylation in gastric cancer.
Wang X; Lau KK; So LK; Lam YW
J Biomed Sci; 2009 Oct; 16(1):95. PubMed ID: 19840376
[TBL] [Abstract][Full Text] [Related]
4. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
5. CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.
Fujita T; Igarashi J; Okawa ER; Gotoh T; Manne J; Kolla V; Kim J; Zhao H; Pawel BR; London WB; Maris JM; White PS; Brodeur GM
J Natl Cancer Inst; 2008 Jul; 100(13):940-9. PubMed ID: 18577749
[TBL] [Abstract][Full Text] [Related]
6. Silencing of CHD5 gene by promoter methylation in leukemia.
Zhao R; Meng F; Wang N; Ma W; Yan Q
PLoS One; 2014; 9(1):e85172. PubMed ID: 24454811
[TBL] [Abstract][Full Text] [Related]
7. Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer.
Mulero-Navarro S; Esteller M
Epigenetics; 2008; 3(4):210-5. PubMed ID: 18698156
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic silencing of CHD5, a novel tumor-suppressor gene, occurs in early colorectal cancer stages.
Fatemi M; Paul TA; Brodeur GM; Shokrani B; Brim H; Ashktorab H
Cancer; 2014 Jan; 120(2):172-80. PubMed ID: 24243398
[TBL] [Abstract][Full Text] [Related]
9. CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.
Wong RR; Chan LK; Tsang TP; Lee CW; Cheung TH; Yim SF; Siu NS; Lee SN; Yu MY; Chim SS; Wong YF; Chung TK
Gynecol Obstet Invest; 2011; 72(3):203-7. PubMed ID: 21860208
[TBL] [Abstract][Full Text] [Related]
10. CHD5 a tumour suppressor is epigenetically silenced in hepatocellular carcinoma.
Zhao R; Wang N; Huang H; Ma W; Yan Q
Liver Int; 2014 Jul; 34(6):e151-60. PubMed ID: 24529164
[TBL] [Abstract][Full Text] [Related]
11. The involvement of CHD5 hypermethylation in laryngeal squamous cell carcinoma.
Wang J; Chen H; Fu S; Xu ZM; Sun KL; Fu WN
Oral Oncol; 2011 Jul; 47(7):601-8. PubMed ID: 21636313
[TBL] [Abstract][Full Text] [Related]
12. Role of CHD5 in human cancers: 10 years later.
Kolla V; Zhuang T; Higashi M; Naraparaju K; Brodeur GM
Cancer Res; 2014 Feb; 74(3):652-8. PubMed ID: 24419087
[TBL] [Abstract][Full Text] [Related]
13. CHD5, a tumor suppressor that is epigenetically silenced in lung cancer.
Zhao R; Yan Q; Lv J; Huang H; Zheng W; Zhang B; Ma W
Lung Cancer; 2012 Jun; 76(3):324-31. PubMed ID: 22186629
[TBL] [Abstract][Full Text] [Related]
14. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
[TBL] [Abstract][Full Text] [Related]
15. mRNA expression and epigenetic-based role of chromodomain helicase DNA-binding 5 in hepatocellular carcinoma.
Heidari Z; Asemi-Rad A; Moudi B; Mahmoudzadeh-Sagheb H
J Int Med Res; 2022 Jul; 50(7):3000605221105344. PubMed ID: 35808817
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of CHD5 Inactivation in neuroblastomas.
Koyama H; Zhuang T; Light JE; Kolla V; Higashi M; McGrady PW; London WB; Brodeur GM
Clin Cancer Res; 2012 Mar; 18(6):1588-97. PubMed ID: 22294723
[TBL] [Abstract][Full Text] [Related]
17. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
18. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
19. CHD5 is a potential tumor suppressor in non small cell lung cancer (NSCLC).
Baykara O; Tansarikaya M; Bulut P; Demirkaya A; Buyru N
Gene; 2017 Jun; 618():65-68. PubMed ID: 28400267
[TBL] [Abstract][Full Text] [Related]
20. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]